Vaxcyte’s 31-Strain Pneumococcal Vaccine Clears a Phase 3 Milestone

Vaxcyte says its experimental pneumococcal vaccine, VAX-31, met the primary endpoints in a Phase 3 trial in adults. The candidate is designed to cover 31 bacterial serotypes—strains that can cause pneumococcal disease, including pneumonia—compared with 20 covered by Pfizer’s Prevnar and 21 by Merck’s Capvaxive. BioPharma Dive reports that VAX-31 matched the existing vaccines’ effectiveness against nearly all strains in this first of **three planned Phase 3...